MedTrace Logo

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

NCT00002441 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV. Patients who become infected despite immunization will be studied to see if receiving the vaccine before becoming infected will help keep HIV levels (viral load) low.

Conditions

  • HIV Infections
  • HIV Seronegativity

Interventions

BIOLOGICAL

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

Sponsors & Collaborators

  • VaxGen

    lead INDUSTRY

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States
  • Canada
  • Netherlands
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002441 on ClinicalTrials.gov